Tamoxifenum

Tamoxifenum est prodroga, at metaboliti activi eius, Afimoxifenum et Endoxifenum potissime receptoriis oestrogenii adiungunt. Usus est therapia et complementum cancri mammae^[1].

Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.

Tamoxifenum
Natura chemica


Formula chemica	C₂₆H₂₉NO
Massa molaris	371.515 g/mol
PubChem	2733526
DrugBank	DB00675
Natura pharmacologica
Codex ATC	L02BA01 (WHO)
Tempus semivitae biologicum	5-7 dies
Metabolismus	iecore (hepaticus)
Metabolitus	Afimoxifenum, Endoxifenum
Substratum enzymi	CYP2C9 CYP2D6 CYP3A4
Excretio	faecibus 65%, renibus 9%
Ad usum therapeuticum
Applicatio	per os
MedlinePlus	a682414 (Anglice)

Tamoxifenum in ordinis mundi sanitarii indicem exemplarem medicamentorum essentialium receptum est.

Natura Tamoxifeni

Natura chemica

Nomen IUPAC suum est (Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethyl-aethylaminum. Formula chemica summa Ciprofloxacini est C₂₆H₂₉NO , massa molaris sua 371.515 g/mol.

Natura pharmacologica

Tamoxifenum est aromatasis inhibitor. Substantia in codice ATC reperitur: L02BA01 (WHO).

Effectus Tamoxifeni

Effectus non grati

Cum Tamoxifeni consumptione effectus secundarios et interactiones observati sunt, per exemplo:

in cerebro: cognitionis impedimentum^[2]
in oculis: oedema maculae, opacidades corneales, retinopathiae, cataracta
in corde: intervallum QT prolongatum
in iecore: transaminasum augmen

Nexus interni

Cancer mammae

Notae

↑ Criscitiello C, Fumagalli D, Saini KS, Loi S (2010). "Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection". Onco Targets Ther 4: 1-11
↑ Paganini-Hill A, Clark LJ (2000). "Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen". Breast Cancer Res Treat 64 (2): 165-76

Nexus externi

Drugs.com: de Tamoxifeno. (Anglice)

[1] Criscitiello C, Fumagalli D, Saini KS, Loi S (2010). "Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection". Onco Targets Ther 4: 1-11

[2] Paganini-Hill A, Clark LJ (2000). "Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen". Breast Cancer Res Treat 64 (2): 165-76

[1]

[2]